Drug Guide
Promethazine Hydrochloride
Classification
Therapeutic: Antiemetic, Antihistamine
Pharmacological: Phenothiazine antihistamine
FDA Approved Indications
- Nausea and vomiting
- Allergic conditions (rhinitis, conjunctivitis, etc.)
- Preoperative sedation
- Motion sickness
Mechanism of Action
Promethazine exerts its effects primarily by antagonizing histamine H1 receptors, thereby reducing allergic symptoms and nausea. It also has central sedative properties through CNS depression and anticholinergic effects that contribute to its antiemetic action.
Dosage and Administration
Adult: Typically 12.5 to 25 mg every 4 to 6 hours as needed, not to exceed 100 mg per day
Pediatric: For children 2 years and older, 0.25 to 0.5 mg/kg every 4 to 6 hours, not to exceed 25 mg per dose or 75 mg per day
Geriatric: Start at lower doses, closely monitor for CNS and anticholinergic side effects
Renal Impairment: Adjust dosage based on severity, consult specific guidelines
Hepatic Impairment: Use with caution, start at lower doses
Pharmacokinetics
Absorption: Well absorbed from gastrointestinal tract
Distribution: Widely distributed, crosses blood-brain barrier and placenta
Metabolism: Extensively metabolized in the liver
Excretion: Primarily via renal route as metabolites
Half Life: approximately 10-19 hours depending on individual factors
Contraindications
- Coma
- Ex coma state or CNS depression caused by alcohol, hypnotics, opioids, or other CNS depressants
- Children under 2 years old due to risk of respiratory depression
Precautions
- Use with caution in elderly, those with respiratory issues, or with known hypersensitivity to phenothiazines. Risk of neuroleptic malignant syndrome, extrapyramidal symptoms, and severe respiratory depression in children.
Adverse Reactions - Common
- Drowsiness (Common)
- Dizziness (Common)
- Dry mouth (Common)
- Dizziness (Common)
Adverse Reactions - Serious
- Respiratory depression in children (Rare)
- Extrapyramidal symptoms (Rare)
- Neuroleptic malignant syndrome (Very rare)
Drug-Drug Interactions
- Additive sedation with CNS depressants
- Potential for increased anticholinergic effects when combined with other anticholinergic drugs
Drug-Food Interactions
- Alcohol can increase sedative effects
Drug-Herb Interactions
N/ANursing Implications
Assessment: Monitor for efficacy (control of nausea/vomiting/allergic symptoms) and adverse effects (sedation, dry mouth, respiratory issues).
Diagnoses:
- Risk for sedation or respiratory depression
- Risk for falls in elderly
Implementation: Administer after meals to reduce GI distress, avoid alcohol, and closely observe for respiratory depression in children.
Evaluation: Assess symptom relief and monitor for adverse reactions.
Patient/Family Teaching
- Avoid alcohol and other CNS depressants.
- Report excessive drowsiness, respiratory difficulty, or allergic reactions.
- Do not operate heavy machinery until effects are known.
- Use caution in elderly due to increased risk of falls or confusion.
Special Considerations
Black Box Warnings:
- Respiratory depression in children under 2 years old, especially with IV use
- Use in pediatric patients under 2 years is contraindicated due to increased risk of respiratory depression.
Genetic Factors: None specifically noted.
Lab Test Interference: Potential false-positive skin test reactions and possible interference with certain diagnostic tests.
Overdose Management
Signs/Symptoms: Extreme sedation, respiratory depression, seizures, hallucinations, coma.
Treatment: Supportive care, airway management, activated charcoal if ingestion was recent, and specific interventions for respiratory or cardiac support as needed.
Storage and Handling
Storage: Store at controlled room temperature, 15-30°C (59-86°F).
Stability: Stable when properly stored, use before expiration date.